ACDC
High-CBD, low-THC cannabis strain bred from Cannatonic for non-intoxicating use.
Growing, buying or possessing cannabis and seeds is legal only in some places. Check the law where you live before acting on this information.
ACDC's value is real but narrow: a high-CBD, low-THC flower for people who want to smoke or vape cannabis without getting high. The cannabinoid ratio is measurable and consistent. Everything beyond that — specific medical claims, signature terpene profiles, guaranteed genetics from seeds — is extrapolation or folklore. Buy from verified clones and lab-tested batches.
Overview
ACDC is a CBD-dominant phenotype selected from Cannatonic, a hybrid bred by Resin Seeds in Spain in the late 2000s. It became widely known in the United States after testing by analytical labs in California and Colorado consistently showed CBD:THC ratios near 20:1, with CBD often above 15% and THC below 1% Strong evidence[1].
Unlike most popular cultivars, ACDC's reputation rests on a measurable chemical signature rather than aroma, yield, or potency in the THC sense. It is the strain people reach for when they explicitly do not want to get high.
Because cannabis genetics propagate informally and there is no central registry, the 'ACDC' available at one dispensary may not be genetically identical to 'ACDC' at another. What matters for consumer purposes is the lab result: if it tests at ~20:1 CBD:THC, it is functionally ACDC regardless of pedigree claims.
Chemistry
ACDC is a Type III (CBD-dominant) chemotype Strong evidence. Cannabis plants express one of three main chemotypes based on enzymatic alleles that direct CBGA (the precursor) toward either THCA or CBDA synthesis. Type III plants express the CBDA-synthase allele and accumulate CBD as their dominant cannabinoid.
Cannabinoid profile
Typical lab results for ACDC flower:
- CBD: 14–24%
- THC: 1–6% (often under 1% in well-selected cuts)
- Ratio: ~20:1 CBD:THC Strong evidence[1]
The cannabinoid ratio is reliable and measurable when sourced from a verified clone and submitted to a reputable lab Strong evidence. However, lab results vary across growers, soil profiles, and testing facilities. Always verify a batch with a certificate-of-analysis-coa before purchase.
Terpene profile
Terpenes in ACDC vary considerably between growers and labs. Reported dominant terpenes include myrcene, β-caryophyllene, and pinene, but there is no single 'ACDC terpene profile' that holds across cultivators Weak / limited[2].
Claims that any specific terpene threshold (e.g. 'myrcene-0-5-percent-threshold') predicts effects are folklore, not established science Disputed.
Reported effects
There are no clinical trials on ACDC specifically, and no controlled studies comparing it to other cultivars No data. What follows is user-reported and should be read as anecdotal.
Users typically report:
- Minimal to no intoxication, even at moderate doses Anecdote
- Reduced anxiety or muscle tension Anecdote
- Mental clarity compared to THC-dominant strains Anecdote
These reports align with what is known about CBD pharmacology in general. CBD is not intoxicating at typical doses, and in controlled human trials has shown anxiolytic effects Strong evidence[3]. When co-administered with THC, CBD can blunt some of THC's psychoactive effects Strong evidence[4].
However, generalizing from 'CBD works in a clinical trial' to 'ACDC will do X for you' skips several steps. Dose, route (smoked vs. vaporized vs. extracted), individual metabolism, expectation, and setting all influence the outcome.
The FDA has approved only one cannabis-derived CBD product—Epidiolex (purified cannabidiol)—for specific seizure disorders Strong evidence[5]. ACDC flower is not that product and has not undergone medical trials.
Lineage
ACDC is generally described as a phenotype of Cannatonic, which Resin Seeds created by crossing a female MK Ultra with a male G13 Haze. Cannatonic itself segregates into Type I, II, and III phenotypes; ACDC is the Type III selection that stabilized for high CBD and low THC.
Beyond that, lineage becomes unclear. The specific cut popularized in the US is variously attributed to growers in northern California, but verification is not possible due to informal cannabis genetics propagation. Several seed banks now sell 'ACDC' seeds whose genetic relationship to the original clone is unverifiable Disputed.
The practical consequence: seed-grown ACDC will not reliably produce the parent's high-CBD phenotype. Serious growers work from verified clones and confirm chemotype with lab testing before committing to a mother plant Strong evidence.
Cultivation
ACDC is considered moderately difficult to grow well Anecdote.
Structure and care
- Growth habit: Tall, lanky, sativa-leaning structure that benefits from topping and trellising
- Flowering time: 9–10 weeks indoors
- Yield: Moderate indoors (~400 g/m²); reports vary widely Anecdote
- Environment: Susceptible to powdery mildew in humid conditions; benefits from low-stress training and good air circulation
Genetic drift
The more important issue with ACDC is genetic stability from seed. Because the popular ACDC cut is heterozygous (carries mixed alleles), seed-grown offspring will segregate across chemotypes. Only a small fraction of seedlings will express the high-CBD, low-THC phenotype Strong evidence. Growers looking for consistent ACDC chemistry must source verified clones and confirm the phenotype with lab testing.
Buying 'ACDC seeds' and assuming the result will be 20:1 CBD:THC is a common and expensive mistake.
Marketing vs. reality
What's real
- ACDC is genuinely CBD-dominant when sourced from a verified cut and tested batch Strong evidence
- It produces little to no intoxication at typical doses Strong evidence
- The cannabinoid ratio (~20:1) is consistent and measurable Strong evidence
What's marketing or folklore
- Specific medical claims ('ACDC treats anxiety/pain/epilepsy') — these extrapolate from CBD pharmacology research, not from ACDC trials No data
- Signature terpene profile or 'entourage effect' producing strain-specific outcomes — terpene profiles vary widely between batches, and no strain-specific mechanism has been established Disputed
- Indica/sativa-myth descriptors applied to ACDC — these categories don't reliably predict effects in any strain Disputed[2]
- Seed-grown ACDC reliably reproducing parent chemistry — it does not Strong evidence
ACDC's honest value proposition is narrow and useful: a high-CBD, low-THC flower for people who want the ritual and route-of-administration of smoking or vaporizing cannabis without significant intoxication. That's a real offering. Everything beyond that is extrapolation or marketing.
Frequently asked questions
Is ACDC indica or sativa?
ACDC has a sativa-leaning growth structure and does not fit neatly into either category. These labels don't reliably predict effects—see indica-sativa-myth. What matters is the cannabinoid and terpene profile, not the morphology.
What's the THC level in ACDC?
Typically 1–6%, often under 1% in well-cultivated cuts. Always verify with a lab test; two batches sold as ACDC may differ significantly.
How long is the flowering time?
9–10 weeks indoors. This varies by phenotype and growing conditions.
Who bred ACDC?
Resin Seeds bred the parent strain Cannatonic in Spain in the late 2000s. The specific ACDC phenotype was selected and popularized by California growers, but there is no single definitive 'breeder' of ACDC itself. The genetics have since been propagated informally and are no longer under controlled breeding.
Sources
- Reported Leafly. 'ACDC Strain.' Leafly Strain Database, aggregated lab data from licensed testing facilities.
- Peer-reviewed de Meijer, E.P.M., Bagatta, M., Carboni, A., et al. (2003). 'The Inheritance of Chemical Phenotype in Cannabis sativa L.' Genetics, 163(1), 335–346.
- Peer-reviewed Smith, C.J., Vergara, D., Keegan, B., Jikomes, N. (2022). 'The phytochemical diversity of commercial Cannabis in the United States.' PLOS ONE, 17(5), e0267498.
- Peer-reviewed Bergamaschi, M.M., Queiroz, R.H., Chagas, M.H., et al. (2011). 'Cannabidiol reduces the anxiety induced by simulated public speaking in treatment-naïve social phobia patients.' Neuropsychopharmacology, 36(6), 1219–1226.
- Peer-reviewed Boggs, D.L., Nguyen, J.D., Morgenson, D., Taffe, M.A., Ranganathan, M. (2018). 'Clinical and Preclinical Evidence for Functional Interactions of Cannabidiol and Δ9-Tetrahydrocannabinol.' Neuropsychopharmacology, 43(1), 142–154.
- Government U.S. Food and Drug Administration (2018, updated). 'FDA approves first drug comprised of an active ingredient derived from marijuana to treat rare, severe forms of epilepsy.' FDA News & Events.
- Peer-reviewed Watts, S., McElroy, M., Migicovsky, Z., Maassen, H., van Velzen, R., Myles, S. (2021). 'Cannabis labelling is associated with genetic variation in terpene synthase genes.' Nature Plants, 7, 1330–1334.
How this page was made
Generation history
Drafted with AI assistance and checked by a separate automated fact-check pass. Not every article has been read by a person. See how articles are made.
Related
- Alaskan Thunder Fuck — Sativa-dominant strain with contested origins and a persistent reputation among growers.
- Certificate of Analysis (COA) — Lab-issued document reporting cannabinoid potency and contaminant screening for a specific...
- The Indica/Sativa Myth — The popular classification system contradicts genetics, chemistry, and controlled research...
- The Myrcene 0.5% Threshold — A viral cannabis rule with no peer-reviewed evidence behind it.